Aktiesnakken — Marts 2010
-
At an interim survival analysis in January 2009, the study did not fulfill a criterion for early stopping after half the trial was completed
-
An Independent Data Monitoring Committee (IDMC) has evaluated the interim results and concluded that the benefit-risk profile of zalutumumab
-
he IDMC recommended that the trial should continue to enroll up to 273 patients and a final analysis performed. The final analysis will take
-
take place once 231 deaths have occurred.
-
Jun 10, 2009
Recruitment Completed in Zalutumumab Head and Neck Cancer Pivotal Study -
du poster i debatten ikke?
-
jeg tror vi blev i tvivl om hvor syge de var....men jeg ville tage worst case, det vil sige at de er i god fatning
-
worst case er worst case
Jeg går ud fra at benchmark iøvrigt er Erbitux? -
ja det er det der er tricky dicky solsen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind